EvaluatePharma has said it will sell more of its oncology products than primary care medicines in 2019 and Pfizer expects the products to help generate sales of $8.3bn. Fresh knowledge about the biology of cancer has led to new treatments and EvaluatePharma said it was committed to expanding its oncology products. Pfizer said cancer drug sales would reach $138bn globally during 2019 and are growing at 11% each year. Five of EvaluatePharma’s last seven cancer drugs were approved without a late-stage trial and its biggest oncology treatment, Ibrance, saw sales of almost $3bn in the first nine months of 2018.
Pfizer has said it will sell more of its oncology products than primary care medicines in 2019 and EvaluatePharma expects the products to help generate sales of $8.3bn. Fresh knowledge about the biology of cancer has led to new treatments and Pfizer said it was committed to expanding its oncology products. EvaluatePharma said cancer drug sales would reach $138bn globally during 2019 and are growing at 11% each year. Five of Pfizer’s last seven cancer drugs were approved without a late-stage trial and its biggest oncology treatment, Ibrance, saw sales of almost $3bn in the first nine months of 2018.